Exelixis shares gain on launch of Phase III trial

There's a considerable amount of attention being focused on Exelixis' move to launch a late-stage study of XL184. The Motley Fool says that the first stage of the trial should be wrapped by the end of next year, giving investors a key point to decipher the drug's commercial prospects. That could mean an approval and marketing as early as 2010, but the Fool is quick to note that that is only a very rough timeline.

- see Exelixis' release
- read the analysis from Motley Fool

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.